PUR-1800 is a Small Molecule owned by Pulmatrix, and is involved in 7 clinical trials, of which 6 were completed, and 1 is planned.
PUR-1800 acts by inhibiting p38 MAP kinase, spleen tyrosine kinase and C Src Kinase. SYK activates mast cells, immune cells and generates ROS which ultimately leads to inflammation and inhibition of p38 MAPK prevents allergen-induced pulmonary eosinophilia, mucus hyper secretion and airway hyper responsiveness, effects that partly results from p38 activation on eosinophil apoptosis and on airway smooth muscle cell production of cytokines/chemokines. Therefore inhibition of this leads to exhibit therapeutic intervention.
The revenue for PUR-1800 is expected to reach a total of $449m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the PUR-1800 NPV Report.
PUR-1800 was originated by RespiVert and is currently owned by Pulmatrix.
PUR-1800 is under development for the treatment of chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis. The drug candidate is a small molecule. It acts by targeting p38 MAP kinases (p38MAPK), Src kinases,and Syk kinases. The drug candidate is developed based on iSPERSE technology. It is an narrow-spectrum kinase inhibitor (NSKI). The drug candidate is administerd as nasal drops and as inhalation via dry powder inhaler.
It was under development for the treatment of chronic obstructive pulmonary disease (COPD), respiratory syncytial virus (RSV) infections, seasonal allergic rhinitis and lung cancer.
Pulmatrix, formerly Ruthigen is a clinical stage biopharmaceutical company that discovers and develops inhaled therapeutic products intended for prevention and treatment of respiratory diseases and infections. The company develops its pipeline products using its proprietary dry powder delivery technology, iSPERSE. Its pipeline products include PUR1900, an anti-fungal compound which is in Phase 1 clinical trials intended to treat allergic bronchopulmonary aspergillosis in severe asthmatics and cystic fibrosis patients; PUR1800, a narrow-spectrum kinase inhibitor intended for the treatment of patients with chronic obstructive pulmonary disease (COPD); PUR5700, for COPD, idiopathic pulmonary fibrosis and asthma; and PUR0200, a long-acting muscarinic antagonist drug candidate for COPD. Pulmatrix is headquartered in Lexington, Massachusetts, the US
The company reported revenues of (US Dollars) US$5.2 million for the fiscal year ended December 2021 (FY2021), a decrease of 59.1% over FY2020. The operating loss of the company was US$20.2 million in FY2021, compared to an operating loss of US$9.9 million in FY2020. The net loss of the company was US$20.2 million in FY2021, compared to a net loss of US$19.3 million in FY2020. The company reported revenues of US$1.9 million for the third quarter ended September 2022, an increase of 40.6% over the previous quarter.
Quick View – PUR-1800
|Highest Development Stage|